It may be related to prolonged receptor occupancy of PD-L1 antibodies [37,50], higher levels of proinflammatory cytokines observed in the combination therapy [43], and enhanced T-cell mediated killing of tumor cells by cytokine-induced MHC class-I presentation [42]. The gene discussed is CD274; the disease is neoplasm.